Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization.

Brozzo MS, Bjelić S, Kisko K, Schleier T, Leppänen VM, Alitalo K, Winkler FK, Ballmer-Hofer K.

Blood. 2012 Feb 16;119(7):1781-8. doi: 10.1182/blood-2011-11-390922. Epub 2011 Dec 29.

2.

Structural determinants of growth factor binding and specificity by VEGF receptor 2.

Leppänen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K, Alitalo K.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2425-30. doi: 10.1073/pnas.0914318107.

3.

Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites.

Hyde CA, Giese A, Stuttfeld E, Abram Saliba J, Villemagne D, Schleier T, Binz HK, Ballmer-Hofer K.

Mol Cell Biol. 2012 Oct;32(19):3802-13. doi: 10.1128/MCB.06787-11. Epub 2012 Jul 16. Review.

4.

Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation.

Leppänen VM, Tvorogov D, Kisko K, Prota AE, Jeltsch M, Anisimov A, Markovic-Mueller S, Stuttfeld E, Goldie KN, Ballmer-Hofer K, Alitalo K.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):12960-5. doi: 10.1073/pnas.1301415110. Epub 2013 Jul 22.

5.

Structural determinants of vascular endothelial growth factor-D receptor binding and specificity.

Leppänen VM, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, Toivanen P, Ylä-Herttuala S, Ballmer-Hofer K, Alitalo K.

Blood. 2011 Feb 3;117(5):1507-15. doi: 10.1182/blood-2010-08-301549. Epub 2010 Dec 8.

6.

Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.

Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K.

J Biol Chem. 2006 Apr 28;281(17):12187-95. Epub 2006 Feb 27.

7.

Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers.

Dosch DD, Ballmer-Hofer K.

FASEB J. 2010 Jan;24(1):32-8. doi: 10.1096/fj.09-132670. Epub 2009 Sep 2.

PMID:
19726758
8.

Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding.

Iyer S, Scotney PD, Nash AD, Ravi Acharya K.

J Mol Biol. 2006 May 26;359(1):76-85. Epub 2006 Apr 17.

PMID:
16616187
9.

Structural analysis of vascular endothelial growth factor receptor-2/ligand complexes by small-angle X-ray solution scattering.

Kisko K, Brozzo MS, Missimer J, Schleier T, Menzel A, Leppänen VM, Alitalo K, Walzthoeni T, Aebersold R, Ballmer-Hofer K.

FASEB J. 2011 Sep;25(9):2980-6. doi: 10.1096/fj.11-185397. Epub 2011 May 25.

PMID:
21613573
10.

Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites.

Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, Claesson-Welsh L.

J Biol Chem. 2003 Oct 17;278(42):40973-9. Epub 2003 Jul 24.

12.

Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.

Tvorogov D, Anisimov A, Zheng W, Leppänen VM, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, Kalkkinen N, Lankinen H, Ojala PM, Alitalo K.

Cancer Cell. 2010 Dec 14;18(6):630-40. doi: 10.1016/j.ccr.2010.11.001. Epub 2010 Dec 2.

13.

The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands.

Anisimov A, Leppänen VM, Tvorogov D, Zarkada G, Jeltsch M, Holopainen T, Kaijalainen S, Alitalo K.

Sci Signal. 2013 Jul 2;6(282):ra52. doi: 10.1126/scisignal.2003905.

PMID:
23821770
14.

Structure of a VEGF-VEGF receptor complex determined by electron microscopy.

Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K.

Nat Struct Mol Biol. 2007 Mar;14(3):249-50. Epub 2007 Feb 11.

PMID:
17293873
15.

VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis.

Zhang L, Zhou F, Han W, Shen B, Luo J, Shibuya M, He Y.

Cell Res. 2010 Dec;20(12):1319-31. doi: 10.1038/cr.2010.116. Epub 2010 Aug 10.

PMID:
20697430
16.

Bovine papular stomatitis virus encodes a functionally distinct VEGF that binds both VEGFR-1 and VEGFR-2.

Inder MK, Ueda N, Mercer AA, Fleming SB, Wise LM.

J Gen Virol. 2007 Mar;88(Pt 3):781-91.

PMID:
17325350
17.

An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.

Kendrew J, Eberlein C, Hedberg B, McDaid K, Smith NR, Weir HM, Wedge SR, Blakey DC, Foltz I, Zhou J, Kang JS, Barry ST.

Mol Cancer Ther. 2011 May;10(5):770-83. doi: 10.1158/1535-7163.MCT-10-0876. Epub 2011 Mar 9.

18.
19.

Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity.

Alam A, Herault JP, Barron P, Favier B, Fons P, Delesque-Touchard N, Senegas I, Laboudie P, Bonnin J, Cassan C, Savi P, Ruggeri B, Carmeliet P, Bono F, Herbert JM.

Biochem Biophys Res Commun. 2004 Nov 12;324(2):909-15.

PMID:
15474514
20.

Supplemental Content

Support Center